1.63
+3.82%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About PAVmed
From its filings with the US Securities and Exchange Commission
PAVmed is based in New York, New York and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker PAVM. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2024, it reported revenue of $3.0m.
PAVmed is a diversified commercial-stage life sciences company operating in the medical device, diagnostics, and digital health sectors. It operates through multiple independently financed subsidiaries under a shared services model. The Company’s strategy is to advance and commercialize innovative healthcare technologies through its subsidiaries while maintaining flexibility to structure financing at either the PAVmed level or within its subsidiaries.
The Company’s subsidiaries include Lucid Diagnostics, a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device, of which the Company is the largest voting stockholder, and Veris Health, a majority-owned digital health company focused on improving personalized cancer care during treatment and throughout survivorship through digital health tools and the development of an implantable physiological monitor designed to interface with the Veris Cancer Care Platform.
PAVmed continues to support the commercial expansion of EsoGuard through Lucid Diagnostics and to pursue strategic partnerships to expand adoption of the Veris Cancer Care Platform. In addition, PAVmed is developing a medical device portfolio, including its PortIO implantable intraosseous vascular access device and recently licensed endoscopic imaging technology from Duke University. The Company continues to evaluate opportunities to expand its portfolio through internal development and external licensing.
Quoted from its 10-K, filed 27 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 27 Jul 2016
- Employees
- 41
- Website
- pavm.com ↗
- Head office
- 360 MADISON AVENUE, NEW YORK, NY, 10017
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Lishan AklogChairman of the Board, Chief Executive Officer$1.4m
- Mr. Dennis McgrathPresident, Chief Financial Officer$1.1m
- Mr. Michael GlennonIndependent Vice Chairman of the Board$190,250
- Mr. Shaun O'NeilChief Operating Officer, Executive Vice President$1.0m
- Mr. Michael GordonGeneral Counsel, Secretary$1.1m
- Mr. Sundeep AgrawalDirector$317,299
- Mr. Timothy BaxterIndependent Director$200,250
- Mr. Ronald SparksIndependent Director$213,250
- Ms. Debra WhiteIndependent Director$210,250
- Mr. Matt RileyDirector of Investor Relations, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 52
- Environment
- 27
- Social
- 79
- Governance
- 50
- Direct emissions (scope 1)
- 65.44 t
- Energy emissions (scope 2)
- 50.35 t
- Women in the workforce
- 59.48276%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- PAVmed develops innovative medical devices like PortIO and CarpX for vascular access and carpal tunnel treatment.
- The company's DisappEAR uses aqueous silk technology for antibiotic-eluting ear tubes, offering a unique solution.
- PAVmed's NextCath self-anchoring catheter eliminates traditional suturing methods, improving patient care.
Weaknesses
- PAVmed has only 41 employees, which may limit its operational capacity and market reach.
- The company's IPO in 2016 has not led to significant market expansion or product diversification.
- PAVmed's product portfolio remains focused on a few specialized medical devices with limited commercial traction.
Opportunities
- PAVmed can expand its product line with the disposable infusion system featuring variable flow resistors for broader medical applications.
- The growing demand for minimally invasive treatments presents an opportunity for PAVmed's CarpX and NextCath devices.
- PAVmed's aqueous silk technology in DisappEAR could attract partnerships with larger healthcare providers.
Threats
- PAVmed faces competition from established medical device companies in the Health Care sector.
- Regulatory challenges in the US Health Care industry could delay product approvals and market entry.
- The limited number of employees may hinder the company's ability to respond to market changes or new regulations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.